One approach, suggested by several studies demonstrating a role for chaperone systems in Tauopathies (Perez et al., 1991; Renkawek et al., 1994; Ostapchenko et al., 2013), is to identify and manipulate specific molecular chaperones that directly or indirectly control Tau aggregation and Tau-induced neurotoxicity in vivo (Blard et al., 2007; Darling et al., 2021). Here, MAPT is linked to tauopathy.